Head-to-head evidence
Asenapine vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: June 2028 · NCT05603104 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Quetiapine (Seroquel)'s landscape